Though it has been reported that therapies targeting vascular endothelial growth factor (VEGF) were associated with hypertension, cardiotoxicity, and thromboembolic events28, 29, no side effects occurred in the NP group in our observation period. Here, VEGFA is linked to hypertensive disorder.